GDNFRalpha, GDNFRalpha extracellular domain (ECD), GDNFRalpha variants, chimeric GDNFRalpha (e.g., GDNFRalpha immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFRalpha-ligands, for example GDNF, by providing GDNFRalpha to the cell. Also provided are methods for using GDNFRalpha, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.
展开▼